Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Golimumab Clear all
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 2, 2026, 2:22 PM EDT
Active, not recruiting Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

NCT02846545
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Golimumab, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
33
States / cities
Little Rock, Arkansas • Newport Beach, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

NCT01230827
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CNTO 148 (Golimumab), Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 2, 2026, 2:22 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Recruiting Phase 3 Interventional

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

NCT05669833
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Guselkumab, Golimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Loxahatchee Groves, Florida • Plant City, Florida • Riverview, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed No phase listed Observational

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308
View directory record Official record
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 2, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

NCT01217814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 2, 2026, 2:22 PM EDT
Completed No phase listed Observational

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

NCT04571697
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Methotrexate, Anti-TNF
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34,647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

NCT00207740
View directory record Official record
Conditions
Asthma
Interventions
CNTO148, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • Stockton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 2, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

CHronic Nonbacterial Osteomyelitis International Registry

NCT04725422
View directory record Official record
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 2, 2026, 2:22 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT00487539
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg, Golimumab 50 mg
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 2, 2026, 2:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

NCT00488774
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Orange, California • Roseville, California • Littleton, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

NCT04891640
View directory record Official record
Conditions
Juvenile Spondyloarthritis
Interventions
Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

NCT00299546
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 2, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional Results available

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

NCT01962974
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab 2 mg/kg IV
Biological
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

NCT00955279
View directory record Official record
Conditions
Sarcoidosis
Interventions
Placebo, Golimumab, Ustekinumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

NCT01362153
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Glendale, Arizona • Aventura, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 2, 2026, 2:22 PM EDT
Completed No phase listed Observational

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

NCT04772248
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, TNF Inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
105,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 2, 2026, 2:22 PM EDT